David Koelle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7782060/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, The, 2000, 356, 645-649.	13.7	505
2	Mucosal Shedding of Human Herpesvirus 8 in Men. New England Journal of Medicine, 2000, 343, 1369-1377.	27.0	440
3	Persistence of HIV-1 receptor–positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nature Medicine, 2009, 15, 886-892.	30.7	341
4	Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. Journal of Experimental Medicine, 2007, 204, 595-603.	8.5	315
5	Autoreactive T Cells in Healthy Individuals. Journal of Immunology, 2004, 172, 5967-5972.	0.8	309
6	Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival. Journal of Clinical Oncology, 2011, 29, 1539-1546.	1.6	272
7	Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature, 2013, 497, 494-497.	27.8	257
8	Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes Journal of Clinical Investigation, 1998, 101, 1500-1508.	8.2	240
9	Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research. Clinical Microbiology Reviews, 2003, 16, 96-113.	13.6	239
10	Frequent Detection of Kaposi's Sarcoma—Associated Herpesvirus (Human Herpesvirus 8) DNA in Saliva of Human Immunodeficiency Virusâ€Infected Men: Clinical and Immunologic Correlates. Journal of Infectious Diseases, 1997, 176, 94-102.	4.0	224
11	High Incidence of Ganciclovirâ€Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy. Journal of Infectious Diseases, 2002, 185, 20-27.	4.0	216
12	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications, 2018, 9, 3868.	12.8	211
13	Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nature Medicine, 2011, 17, 989-995.	30.7	193
14	A Naturally Selected Dimorphism within the HLA-B44 Supertype Alters Class I Structure, Peptide Repertoire, and T Cell Recognition. Journal of Experimental Medicine, 2003, 198, 679-691.	8.5	192
15	Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. Annual Review of Medicine, 2008, 59, 381-395.	12.2	187
16	Asymptomatic Reactivation of Herpes Simplex Virus in Women after the First Episode of Genital Herpes. Annals of Internal Medicine, 1992, 116, 433-437.	3.9	183
17	Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers. Clinical Cancer Research, 2013, 19, 5351-5360.	7.0	176
18	Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi's sarcoma. Journal of Virology, 1997, 71, 7083-7087.	3.4	174

#	Article	IF	CITATIONS
19	Famciclovir for the Suppression of Symptomatic and Asymptomatic Herpes Simplex Virus Reactivation in HIV-Infected Persons: A Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine, 1998, 128, 21.	3.9	156
20	Herpes Simplex Virus Infection of Human Dendritic Cells Induces Apoptosis and Allows Cross-Presentation via Uninfected Dendritic Cells. Journal of Immunology, 2005, 174, 2220-2227.	0.8	152
21	Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions. Journal of Infectious Diseases, 1994, 169, 956-961.	4.0	142
22	Tetramer-Guided Epitope Mapping: Rapid Identification and Characterization of Immunodominant CD4+ T Cell Epitopes from Complex Antigens. Journal of Immunology, 2001, 166, 6665-6670.	0.8	135
23	Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10289-10294.	7.1	133
24	Herpes simplex virus: the importance of asymptomatic shedding. Journal of Antimicrobial Chemotherapy, 2000, 45, 1-8.	3.0	129
25	Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood. Clinical Cancer Research, 2011, 17, 6671-6680.	7.0	128
26	Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. Journal of Virology, 1994, 68, 2803-2810.	3.4	128
27	Primary and Secondary Syphilis Lesions Contain mRNA for Thl Cytokines. Journal of Infectious Diseases, 1996, 173, 491-495.	4.0	121
28	Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma. Cancer Immunology Research, 2014, 2, 1071-1079.	3.4	120
29	HLA-DQ Tetramers Identify Epitope-Specific T Cells in Peripheral Blood of Herpes Simplex Virus Type 2-Infected Individuals: Direct Detection of Immunodominant Antigen-Responsive Cells. Journal of Immunology, 2000, 164, 4244-4249.	0.8	118
30	HSV-2: in pursuit of a vaccine. Journal of Clinical Investigation, 2011, 121, 4600-4609.	8.2	118
31	CD8 CTL from Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells. Journal of Immunology, 2001, 166, 4049-4058.	0.8	117
32	Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18973-18978.	7.1	112
33	HLA-DQB1 codon 57 is critical for peptide binding and recognition Journal of Experimental Medicine, 1996, 183, 1253-1258.	8.5	110
34	Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. Journal of Clinical Investigation, 2001, 107, 505-517.	8.2	109
35	Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet, The, 2012, 379, 641-647.	13.7	104
36	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	103

#	Article	IF	CITATIONS
37	Herpes Simplex Virus Type 1 Renders Infected Cells Resistant to Cytotoxic T-Lymphocyte-Induced Apoptosis. Journal of Virology, 1998, 72, 436-441.	3.4	101
38	Polymorphisms in <i>TLR2</i> Are Associated with Increased Viral Shedding and Lesional Rate in Patients with Genital Herpes Simplex Virus Type 2 Infection. Journal of Infectious Diseases, 2007, 196, 505-509.	4.0	100
39	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clinical Cancer Research, 2019, 25, 1185-1195.	7.0	97
40	Diversity of the CD8 + T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes. Journal of Virology, 2006, 80, 5509-5515.	3.4	95
41	Immunobiology of Varicella-Zoster Virus Infection. Journal of Infectious Diseases, 2018, 218, S68-S74.	4.0	95
42	Tipping the scales of herpes simplex virus reactivation: The important responses are local. Nature Medicine, 1998, 4, 381-382.	30.7	89
43	Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. Journal of Controlled Release, 2010, 148, 327-333.	9.9	89
44	Local CD4 and CD8 T-Cell Reactivity to HSV-1 Antigens Documents Broad Viral Protein Expression and Immune Competence in Latently Infected Human Trigeminal Ganglia. PLoS Pathogens, 2013, 9, e1003547.	4.7	89
45	Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I. Cancer Immunology Research, 2014, 2, 27-36.	3.4	89
46	T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide–MHC complexes. Nature Biotechnology, 2018, 36, 1191-1196.	17.5	85
47	Tegument-Specific, Virus-Reactive CD4 T Cells Localize to the Cornea in Herpes Simplex Virus Interstitial Keratitis in Humans. Journal of Virology, 2000, 74, 10930-10938.	3.4	83
48	High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. Journal of Virology, 1996, 70, 8165-8168.	3.4	83
49	Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. Journal of Clinical Investigation, 2012, 122, 654-673.	8.2	83
50	Worldwide circulation of HSV-2 × HSV-1 recombinant strains. Scientific Reports, 2017, 7, 44084.	3.3	81
51	Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells Infiltrating Human Genital Herpes Lesions. Journal of Virology, 1998, 72, 7476-7483.	3.4	81
52	Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes Journal of Clinical Investigation, 1993, 91, 961-968.	8.2	80
53	Reactivities of Human Sera with Human Herpesvirus-8-Infected BCBL-1 Cells and Identification of HHV-8-Specific Proteins and Glycoproteins and the Encoding cDNAs. Virology, 1998, 243, 208-217.	2.4	76
54	Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunology Research, 2017, 5, 137-147.	3.4	73

#	Article	IF	CITATIONS
55	Diversity in the Acute CD8 T Cell Response to Vaccinia Virus in Humans. Journal of Immunology, 2005, 175, 7550-7559.	0.8	72
56	Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. Journal of Clinical Investigation, 2021, 131, .	8.2	72
57	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	72
58	Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine, 2011, 29, 8520-8529.	3.8	70
59	Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiology, 2010, 5, 221-239.	2.0	68
60	Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. Journal of Virology, 2015, 89, 8219-8232.	3.4	68
61	Chronic Vulvar Ulceration in an Immunocompetent Woman Due to Acyclovirâ€Resistant, Thymidine Kinaseâ€Deficient Herpes Simplex Virus. Journal of Infectious Diseases, 1998, 177, 543-550.	4.0	67
62	Markers of Viral Infection in Monozygotic Twins Discordant for Chronic Fatigue Syndrome. Clinical Infectious Diseases, 2002, 35, 518-525.	5.8	66
63	Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine Administered to Healthy, HSV-2-Seronegative Adults by a Needle-Free Injection System. Vaccine Journal, 2008, 15, 1638-1643.	3.1	65
64	Human Herpesvirus 8 in the Prostate Glands of Men with Kaposi's Sarcoma. Journal of Virology, 1998, 72, 6223-6227.	3.4	64
65	Current status and prospects for development of an HSV vaccine. Vaccine, 2014, 32, 1553-1560.	3.8	62
66	Herpes simplex virus type 2–specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. Blood, 2002, 99, 3844-3847.	1.4	60
67	DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine, 2010, 28, 7483-7491.	3.8	59
68	Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. Journal of Immunology, 1998, 161, 3527-35.	0.8	59
69	T-cell immunity to human alphaherpesviruses. Current Opinion in Virology, 2013, 3, 452-460.	5.4	58
70	T Cell Immunity to Herpes Simplex Viruses in Seronegative Subjects: Silent Infection or Acquired Immunity?. Journal of Immunology, 2003, 170, 4380-4388.	0.8	57
71	Human Herpesvirus 8 Infection and Kaposi's Sarcoma among Human Immunodeficiency Virus–Infected and –Uninfected Women. Journal of Infectious Diseases, 2001, 183, 1130-1134.	4.0	55
72	Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12899-12904.	7.1	55

#	Article	IF	CITATIONS
73	An Extremely Diverse CD4 Response to Vaccinia Virus in Humans Is Revealed by Proteome-Wide T-Cell Profiling. Journal of Virology, 2008, 82, 7120-7134.	3.4	55
74	An Effector Phenotype of CD8 ⁺ T Cells at the Junction Epithelium during Clinical Quiescence of Herpes Simplex Virus 2 Infection. Journal of Virology, 2012, 86, 10587-10596.	3.4	55
75	Virologic and Immunologic Evidence of Multifocal Genital Herpes Simplex Virus 2 Infection. Journal of Virology, 2014, 88, 4921-4931.	3.4	55
76	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses. Journal of Immunology, 2016, 196, 2205-2218.	0.8	55
77	Cytomegalovirus (CMV) Epitope–Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects. Journal of Immunology, 2017, 199, 3187-3201.	0.8	55
78	Evasion of the Mucosal Innate Immune System by Herpes Simplex Virus Type 2. Journal of Virology, 2009, 83, 12559-12568.	3.4	54
79	Diversity in CD8+ T Cell Function and Epitope Breadth Among Persons with Genital Herpes. Journal of Clinical Immunology, 2010, 30, 703-722.	3.8	54
80	Long Term Persistence of Herpes Simplex Virus-Specific CD8+ CTL in Persons with Frequently Recurring Genital Herpes. Journal of Immunology, 2000, 165, 1146-1152.	0.8	52
81	Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends in Immunology, 2001, 22, 583-588.	6.8	52
82	Fulminant, Acyclovir-Resistant, Herpes Simplex Virus Type 2 Hepatitis in an Immunocompetent Woman. Journal of Clinical Microbiology, 2006, 44, 1584-1586.	3.9	50
83	Ultrasensitive Capture of Human Herpes Simplex Virus Genomes Directly from Clinical Samples Reveals Extraordinarily Limited Evolution in Cell Culture. MSphere, 2018, 3, .	2.9	49
84	Antigen‧pecific T Cells Localize to the Uterine Cervix in Women with Genital Herpes Simplex Virus Type 2 Infection. Journal of Infectious Diseases, 2000, 182, 662-670.	4.0	47
85	Prospects for Developing an Effective Vaccine Against Ocular Herpes Simplex Virus Infection. Current Eye Research, 2005, 30, 929-942.	1.5	47
86	Repeatâ€Region Polymorphisms in the Gene for the Dendritic Cell–Specific Intercellular Adhesion Moleculeâ€3–Grabbing Nonintegrin–Related Molecule: Effects on HIVâ€1 Susceptibility. Journal of Infectious Diseases, 2006, 193, 698-702.	4.0	47
87	A Novel DNA Vaccine Technology Conveying Protection against a Lethal Herpes Simplex Viral Challenge in Mice. PLoS ONE, 2013, 8, e76407.	2.5	47
88	Vascular E-Selectin Expression Correlates with CD8 Lymphocyte Infiltration and Improved Outcome in Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2013, 133, 2065-2073.	0.7	46
89	Zoster Vaccination Increases the Breadth of CD4 ⁺ T Cells Responsive to Varicella Zoster Virus. Journal of Infectious Diseases, 2015, 212, 1022-1031.	4.0	45
90	Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. Mucosal Immunology, 2017, 10, 1259-1269.	6.0	45

#	Article	IF	CITATIONS
91	Comparative genomic, transcriptomic, and proteomic reannotation of human herpesvirus 6. BMC Genomics, 2018, 19, 204.	2.8	45
92	A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. Journal of Infectious Diseases, 2019, 220, 990-1000.	4.0	44
93	Definition of epitopes and antigens recognized by vaccinia specific immune responses: Their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine, 2009, 27, G21-G26.	3.8	43
94	Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors. PLoS ONE, 2011, 6, e16819.	2.5	42
95	A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Vaccine, 2016, 34, 101-109.	3.8	42
96	Expression cloning for the discovery of viral antigens and epitopes recognized by T cells. Methods, 2003, 29, 213-226.	3.8	41
97	Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Human Vaccines and Immunotherapeutics, 2014, 10, 3611-3621.	3.3	41
98	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Scientific Reports, 2017, 7, 8653.	3.3	41
99	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
100	HHV-8 infection: a model for reactivation and transmission. Reviews in Medical Virology, 2002, 12, 47-63.	8.3	40
101	Reduced Levels of Neutralizing Antibodies to Kaposi Sarcoma–Associated Herpesvirus in Persons with a History of Kaposi Sarcoma. Journal of Infectious Diseases, 2004, 189, 2016-2022.	4.0	40
102	APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sexually Transmitted Infections, 2010, 86, 202-206.	1.9	40
103	Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function. PLoS Pathogens, 2019, 15, e1007650.	4.7	40
104	CD4 T-Cell Responses to Herpes Simplex Virus Type 2 Major Capsid Protein VP5: Comparison with Responses to Tegument and Envelope Glycoproteins. Journal of Virology, 2000, 74, 11422-11425.	3.4	39
105	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight, 2021, 6, .	5.0	39
106	Dominance and Diversity in the Primary Human CD4 T Cell Response to Replication-Competent Vaccinia Virus. Journal of Immunology, 2007, 178, 6374-6386.	0.8	38
107	Public TCR Use by Herpes Simplex Virus-2–Specific Human CD8 CTLs. Journal of Immunology, 2010, 184, 3063-3071.	0.8	38
108	Immunobiology of Herpes Simplex Virus and Cytomegalovirus Infections of the Fetus and Newborn. Current Immunology Reviews, 2010, 6, 38-55.	1.2	37

#	Article	IF	CITATIONS
109	Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. Journal of Virology, 2015, 89, 8206-8218.	3.4	37
110	An Important Role for Major Histocompatibility Complex Class I-Restricted T Cells, and a Limited Role for Gamma Interferon, in Protection of Mice against Lethal Herpes Simplex Virus Infection. Journal of Virology, 1999, 73, 2058-2063.	3.4	36
111	Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. Journal of General Virology, 2012, 93, 1305-1315.	2.9	35
112	Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. Journal of Infectious Diseases, 2018, 218, 595-605.	4.0	35
113	Expression of Cutaneous Lymphocyte–Associated Antigen and Eâ€selectin Ligand by Circulating Human Memory CD4+T Lymphocytes Specific for Herpes Simplex Virus Type 2. Journal of Infectious Diseases, 2005, 191, 243-254.	4.0	33
114	Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. Journal of General Virology, 2009, 90, 1153-1163.	2.9	33
115	Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clinical and Experimental Immunology, 2011, 167, 47-58.	2.6	33
116	Polyomavirusâ€driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. Molecular Carcinogenesis, 2020, 59, 807-821.	2.7	32
117	Human CD4 + CD25 high Cells Suppress Proliferative Memory Lymphocyte Responses to Herpes Simplex Virus Type 2. Journal of Virology, 2006, 80, 8271-8273.	3.4	31
118	Cellular Immunity in Monozygotic Twins Discordant for Chronic Fatigue Syndrome. Journal of Infectious Diseases, 2002, 185, 828-832.	4.0	30
119	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	30
120	CD4 T-Cell Memory Responses to Viral Infections of Humans Show Pronounced Immunodominance Independent of Duration or Viral Persistence. Journal of Virology, 2013, 87, 2617-2627.	3.4	29
121	Multicenter study of QuantiFERON [®] -TB Gold Plus in patients with active tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 617-621.	1.2	29
122	Vaccines for herpes simplex virus infections. Current Opinion in Investigational Drugs, 2006, 7, 136-41.	2.3	29
123	Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas. Cancer Immunology Research, 2020, 8, 648-659.	3.4	28
124	ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. Journal of Immunological Methods, 2009, 347, 36-45.	1.4	27
125	Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus–specific type 2 immune responses. Journal of Allergy and Clinical Immunology, 2018, 141, 1144-1147.e5.	2.9	27
126	T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity. JCI Insight, 2022, 7, .	5.0	26

#	Article	IF	CITATIONS
127	Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals. PLoS Pathogens, 2021, 17, e1010203.	4.7	24
128	Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Nail´ve and HSV-2-Infected Subjects. Vaccine Journal, 2008, 15, 773-782.	3.1	23
129	Peripheral Blood CD4 T-Cell and Plasmacytoid Dendritic Cell (pDC) Reactivity to Herpes Simplex Virus 2 and pDC Number Do Not Correlate with the Clinical or Virologic Severity of Recurrent Genital Herpes. Journal of Virology, 2012, 86, 9952-9963.	3.4	23
130	Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain. Cancer Immunology Research, 2019, 7, 1727-1739.	3.4	23
131	Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants. Nature Biotechnology, 2022, 40, 1336-1340.	17.5	23
132	A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. Journal of Virology, 2015, 89, 8497-8509.	3.4	22
133	Latent Tuberculosis Infection Test Agreement in the National Health and Nutrition Examination Survey. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 493-500.	5.6	22
134	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. Scientific Reports, 2021, 11, 4290.	3.3	22
135	Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. PLoS Medicine, 2017, 14, e1002475.	8.4	22
136	Preferential presentation of herpes simplex virus T-cell antigen by HLA DQA1*0501/DQB1*0201 in comparison to HLA DQA1*0201/DQB1*0201. Human Immunology, 1997, 53, 195-205.	2.4	21
137	Herpes Simplex Virus Shedding and Plasma Human Immunodeficiency Virus RNA Levels in Coinfected Women. Clinical Infectious Diseases, 2001, 33, 885-890.	5.8	21
138	Copy Number Heterogeneity, Large Origin Tandem Repeats, and Interspecies Recombination in Human Herpesvirus 6A (HHV-6A) and HHV-6B Reference Strains. Journal of Virology, 2018, 92, .	3.4	21
139	Large, Stable, Contemporary Interspecies Recombination Events in Circulating Human Herpes Simplex Viruses. Journal of Infectious Diseases, 2019, 221, 1271-1279.	4.0	21
140	Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS ONE, 2019, 14, e0226320.	2.5	20
141	The viral hypothesis: how herpesviruses may contribute to Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5476-5480.	7.9	20
142	Homing in on the Cellular Immune Response to HSV-2 in Humans*. American Journal of Reproductive Immunology, 2005, 53, 172-181.	1.2	19
143	Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening. Tuberculosis, 2015, 95, 275-287.	1.9	19
144	Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results. Journal of Allergy and Clinical Immunology, 2019, 144, 1413-1416.e7.	2.9	19

#	Article	IF	CITATIONS
145	Development of a lowâ€dose fastâ€dissolving tablet formulation of Newcastle disease vaccine for lowâ€eost backyard poultry immunisation. Veterinary Record, 2014, 174, 504-504.	0.3	18
146	Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis Infection. Open Forum Infectious Diseases, 2018, 5, ofy184.	0.9	18
147	Prevalence of Human Herpesvirus-8 Salivary Shedding in HIV Increases with CD4 Count. Journal of Dental Research, 2004, 83, 639-643.	5.2	17
148	Innate Immune Responses to Herpes Simplex Virus Type 2 Influence Skin Homing Molecule Expression by Memory CD4 + Lymphocytes. Journal of Virology, 2006, 80, 2863-2872.	3.4	17
149	Use of Acyclovir for Suppression of Human Immunodeficiency Virus Infection Is Not Associated with Genotypic Evidence of Herpes Simplex Virus Type 2 Resistance to Acyclovir: Analysis of Specimens from Three Phase III Trials. Journal of Clinical Microbiology, 2010, 48, 3496-3503.	3.9	17
150	In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. Journal of Infectious Diseases, 2016, 214, 23-31.	4.0	17
151	Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents. Virology, 2017, 510, 90-98.	2.4	17
152	Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2). Genes and Immunity, 2019, 20, 112-120.	4.1	17
153	HHV-6B infection, T-cell reconstitution, and graft-vs-host disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1508-1517.	2.4	16
154	Tissue-Resident-Memory CD8+ T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes. Frontiers in Immunology, 2021, 12, 735643.	4.8	15
155	Longitudinal Analysis of Herpes Simplex Virus–Specific CD4+Cell Clonotypes in Infected Tissues and Blood. Journal of Infectious Diseases, 2005, 191, 2012-2021.	4.0	14
156	One-Day Regimen of Valacyclovir for Treatment of Recurrent Genital Herpes Simplex Virus 2 Infection. Sexually Transmitted Diseases, 2008, 35, 383-386.	1.7	14
157	Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers. Antiviral Therapy, 2010, 15, 1141-1149.	1.0	14
158	MHC-peptide ligand interactions establish a functional threshold for antigen-specific T cell recognition. Human Immunology, 1999, 60, 608-618.	2.4	13
159	A Case of Ramsay Hunt-Like Syndrome Caused by Herpes Simplex Virus Type 2. Clinical Infectious Diseases, 2005, 40, 1545-1547.	5.8	13
160	Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells. Journal of Virology, 2017, 91, .	3.4	13
161	Viral Genetics Modulate Orolabial Herpes Simplex Virus Type 1 Shedding in Humans. Journal of Infectious Diseases, 2019, 219, 1058-1066.	4.0	13
162	BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. Blood Advances, 2022, 6, 1732-1740.	5.2	13

#	Article	IF	CITATIONS
163	Advances in the Characterization of the T-Cell Response to Human Herpesvirus-6. Frontiers in Immunology, 2018, 9, 1454.	4.8	12
164	T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components. JCI Insight, 2022, 7, .	5.0	12
165	Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. Journal of Virology, 2019, 93, .	3.4	11
166	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. PLoS Pathogens, 2020, 16, e1008522.	4.7	11
167	Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense. Journal of Immunology, 2019, 202, 2558-2569.	0.8	10
168	Distinct populations of antigen specific tissue resident CD8 T cells in human cervix mucosa. JCI Insight, 2021, 6, .	5.0	10
169	Local Immune Control of Latent Herpes Simplex Virus Type 1 in Ganglia of Mice and Man. Frontiers in Immunology, 2021, 12, 723809.	4.8	10
170	Stability of live attenuated rotavirus vaccine with selected preservatives and primary containers. Vaccine, 2016, 34, 2483-2489.	3.8	9
171	T-cell Responses to HSV-1 in Persons Who Have Survived Childhood Herpes Simplex Encephalitis. Pediatric Infectious Disease Journal, 2017, 36, 741-744.	2.0	9
172	T Cell Immunity to Varicella-Zoster Virus in the Setting of Advanced HIV and Multiple Varicella-Zoster Virus Recurrences. Viral Immunology, 2017, 30, 77-80.	1.3	9
173	Experimental Oral Herpes Simplex Virus-1 (HSV-1) Co-infection in Simian Immunodeficiency Virus (SIV)-Infected Rhesus Macaques. Frontiers in Microbiology, 2017, 8, 2342.	3.5	9
174	Elevated Spontaneous Interferon-Î ³ Secretion in Human Immunodeficiency Virus-Infected Persons. Open Forum Infectious Diseases, 2017, 4, ofx055.	0.9	9
175	Mechanisms of Endogenous HIV-1 Reactivation by Endocervical Epithelial Cells. Journal of Virology, 2020, 94, .	3.4	9
176	Conservation of molecular and cellular phenotypes of invariant NKT cells between humans and non-human primates. Immunogenetics, 2019, 71, 465-478.	2.4	8
177	Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab. Journal of Translational Autoimmunity, 2021, 4, 100114.	4.0	8
178	Proteome-Wide Zika Virus CD4 T Cell Epitope and HLA Restriction Determination. ImmunoHorizons, 2020, 4, 444-453.	1.8	8
179	CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. Nature Communications, 2022, 13, 78.	12.8	8
180	The Murine Intravaginal HSV-2 Challenge Model for Investigation of DNA Vaccines. Methods in Molecular Biology, 2014, 1144, 305-327.	0.9	7

#	Article	IF	CITATIONS
181	HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions. Genes and Immunity, 2016, 17, 412-418.	4.1	6
182	Genome-Wide Approach to the CD4 T-Cell Response to Human Herpesvirus 6B. Journal of Virology, 2019, 93, .	3.4	6
183	Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2. Archives of Virology, 2008, 153, 1165-1169.	2.1	5
184	An interferon-gamma release assay as a novel biomarker in systemic lupus erythematosus. Rheumatology, 2020, 59, 3479-3487.	1.9	5
185	HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens. Frontiers in Immunology, 2022, 13, 867962.	4.8	5
186	Doctor, Why Is My Herpes So Bad? The Search Continues. Journal of Infectious Diseases, 2008, 197, 331-334.	4.0	4
187	Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine. Journal of Infectious Diseases, 2017, 216, 1329-1333.	4.0	4
188	Trillions and Trillions: Herpes Simplex Virus–1 Hepatitis in an Immunocompetent Adult. Open Forum Infectious Diseases, 2019, 6, ofz465.	0.9	4
189	Donor-Derived CD4+ T Cells and Human Herpesvirus 6B Detection After Allogeneic Hematopoietic Cell Transplantation. Journal of Infectious Diseases, 2021, 223, 709-713.	4.0	4
190	Allelic variants of MHC class II Molecules can ACT as partial agonists of antigen-specific T cell responses. Human Immunology, 1996, 47, 149.	2.4	3
191	Peptide binding affinity and pH variation establish functional thresholds for activation of HLA-DQ-restricted T cell recognition. Human Immunology, 1999, 60, 619-626.	2.4	3
192	Persistence of Herpes Simplex Virus Type 2 VP16-Specific CD4+ T Cells. Human Immunology, 2005, 66, 777-787.	2.4	3
193	A Novel Approach of Identifying Immunodominant Self and Viral Antigen Cross-Reactive T Cells and Defining the Epitopes They Recognize. Frontiers in Immunology, 2018, 9, 2811.	4.8	3
194	Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors. Communications Biology, 2022, 5, 133.	4.4	3
195	Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. PLOS Global Public Health, 2022, 2, e0000231.	1.6	3
196	HSV-1 and 2: immunobiology and host response. , 2007, , 616-641.		2
197	Interactions of peptide side chains with structurally complementary pockets in DQ molecules are critical for allele-specific peptide binding and T cell reactivity. Human Immunology, 1996, 47, 17.	2.4	1
198	1154Host and Pathogen Genetics Modulate HSV-1 Severity. Open Forum Infectious Diseases, 2014, 1, S342-S342.	0.9	1

#	Article	IF	CITATIONS
199	Elevated Spontaneous Interferon-Gamma Secretion in HIV-Infected Persons. Journal of Allergy and Clinical Immunology, 2015, 135, AB100.	2.9	1
200	Flt3-L enhances trans-epithelial migration and antigen presentation of dendritic cells adoptively transferred to genital mucosa. Journal of Controlled Release, 2021, 329, 782-793.	9.9	1
201	The Murine Intravaginal HSV-2 Challenge Model for Investigation of DNA Vaccines. Methods in Molecular Biology, 2020, 2060, 429-454.	0.9	1
202	Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. Journal of Clinical Investigation, 2012, 122, 3024-3024.	8.2	1
203	Response of Human Liver Tissue to Innate Immune Stimuli. Frontiers in Immunology, 2022, 13, 811551.	4.8	1
204	:Clinical Virology, 2nd Edition. Clinical Infectious Diseases, 2002, 35, 1578-1578.	5.8	0
205	Abstract IA17: Merkel cell carcinoma therapy with viral oncoprotein-specific T cells in combination with immunostimulatory adjuvants , 2013, , .		0
206	Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine. Blood, 2021, 138, 1556-1556.	1.4	0
207	HLA-B*57:01 Complexed to a CD8 T-Cell Epitope from the HSV-2 ICP22 Protein Binds NK and T Cells through KIR3DL1. Viruses, 2022, 14, 1019.	3.3	0